Private equity specialists Bain Capital and Cinven inked a deal to purchase the Specialty Ingredients unit (LSI) of Switzerland-based pharmaceuticals group Lonza for an enterprise value of CHF4.2 billion ($4.7 billion) in a transaction that is set to close in the second half of this year.
According to Lonza Chairman Albert Baehny, Bain and Cinven have shown an understanding of the value of the experience and expertise of the company’s employees and presented the “most compelling industrial strategy and vision for the business” and are keen to prioritize R&D and innovation . . .
Continue Reading With Our Special Offer
Unlock this article instantly, along with the rest of our premium content and newsletters, with a 20% discount by using the coupon code VIDRIO2021.
Already a subscriber? Log in.